The landscape for biologics to treat patients with psoriasis looks excellent, said April Armstrong, MD, MPH, professor and chief of dermatology at UCLA.
April Armstrong, MD, MPH, professor and chief of dermatology at UCLA, highlights the different benefits of IL-17 and IL-23 inhibitors for treating patients with psoriasis.
Transcript
What are some main differences between IL-17 and IL-23 inhibitors, and is there a preference when treating psoriasis?
IL-23 and IL-17 inhibitors are excellent treatments for patients with moderate to severe plaque psoriasis. I think that one of the key differentiating factors between the 2 of them is that IL-17 inhibitors have very good response in psoriatic arthritis [PsA]; they work very well for both the peripheral as well as axial [PsA]. Now for the IL-23 inhibitors, most of them are also approved for PsA, so we do have some data in that regard as well, but I will say for someone who has severe [PsA], IL-17 inhibitors probably as a class work a bit better in that regard.
IL-23 inhibitors really shine in terms of their fantastic safety record, they are well tolerated by patients, and the safety profile over time is also very good. They also have long-term persistence in the real-world studies, which we have seen, and that is very helpful for patients because we want our patients to be able to not switch from one medication to another and be able to stay on the same medication as long as it works. And I think the IL-23 class as a whole have pretty good persistence of response. In addition to that, we also see that the IL-23 class of medications is really fantastic in terms of infrequent injections. The injection interval is usually between every 2 months to about every 3 months, so you really only get a few doses during the year.
Now, our newer IL-17 inhibitors, and I will say one that was just approved yesterday has the option of also doing 1 injection every 2 months, and that's bimekizumab. So, really hot off the press, we have a new IL-17 inhibitor that just got approved by the FDA. As you can see, the landscape for biologics for patients with psoriasis looks really excellent. We have a number of different options to offer for our patients as well as our clinicians.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More